Products with Cardioprotective bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3502 | Ginsenoside Rk3 |
| Ginsenoside Rk3 is often used as a major ingredient of the compound preparation for ischemic heart diseases, it could have a role in treating inflammatory diseases. Ginsenoside Rk3 significantly inhibits TNF-α-induced NF-κB transcriptional activity, with an IC50 of 14.24±1.30 μM in HepG2 cells. | |
| BCN3539 | Sinapic acid |
| Sinapic acid shows antibacterial, antioxidant, anti-inflammary, and cardiacprotective activities. Sinapic acid ameliorates hyperglycemia through PLC-PKC signals to enhance the glucose utilization in diabetic rats. Sinapic acid is a potentially useful agent for the protection against liver fibrosis and cirrhosis, it protects the rat liver from CCl4-induced inflammation, most likely by acting as a free radical scavenger and modulator of NF-κB p65 activation and proinflammatory cytokine expression. | |
| BCN3669 | Tilianin |
| 1. Tilianin has anti-inflammatory activity. 2. Tilianin has antiatherogenic activity. 3. Tilianin inhibits the tumor necrotic factor-K (TNF-K)-induced expression of VCAM-1 by 74% and reduces TNF-K-induced activation of nuclear factor-UB in cultured human umbilical vein endothelial cells (HUVECs). 4. Tilianin has antihypertensive and vasorelaxant activities, mediates relaxation and antihypertension mainly by an endothelium-dependent manner, probably due to NO release, and also through an endothelium-independent pathway by opening K+ channels. | |
| BCN3706 | 14-Deoxyandrographolide |
| 1. 14-Deoxyandrographolide desensitizes hepatocytes to TNF-alpha-mediated apoptosis through the release of TNFRSF1A. 2. 14-Deoxyandrographolide has hepatoprotective activity, mediates activation of adenylate cyclase-cAMP signaling leading to up-regulation of cNOS, may provide a promising approach in the prevention of liver diseases during chronic alcoholism. | |
| BCN4004 | Moracin O |
| 1. Moracin O and moracin P exhibit potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1), which is a key mediator during adaptation of cancer cells to tumour hypoxia. 2. Moracin O shows significant neuroprotective activity against glutamate-induced cell death in SK-N-SH cells. 3. Moracin O demonstrates a remarkable inhibition of the acetic acid-induced pain. 4. Moracin O has a strong protective influence against doxorubicin-induced cardiomyopathy in H9c2 cells with the EC50 value of 4.5 ± 1.3 uM. | |
